KRTAP22-2: A Drug Target / Disease Biomarker (G100288287)

Target Name: KRTAP22-2

NCBI ID: G100288287

KRTAP22-2

Other Name(s): KAP22.2 | KR222_HUMAN | keratin associated protein 22-2 | Keratin-associated protein 22-2 | Keratin associated protein 22-2

KRTAP22-2: A Drug Target / Disease Biomarker

KRTAP22-2 is a protein that is expressed in the brain and is known for its role in the regulation of pain signaling. It is a potential drug target for several diseases, including chronic pain and neurodegenerative disorders.

KRTAP22-2 is a member of the KRTAP family, which is known for its role in the regulation of protein synthesis and stability. The KRTAP family consists of four subunits: KRTAP1, KRTAP2, KRTAP3, and KRTAP4. KRTAP22-2 is the latest member of this family and is expressed in the brain.

KRTAP22-2 is involved in the regulation of pain signaling pathways. It is known to play a role in the regulation of neurotransmitter release from pain interneurons, which are responsible for generating pain signals. KRTAP22-2 is also involved in the regulation of the expression of pain-related genes.

In addition to its role in pain signaling, KRTAP22-2 is also thought to be involved in the regulation of other cellular processes. It is known to play a role in the regulation of cell survival and has been shown to be involved in the regulation of cell proliferation and differentiation.

KRTAP22-2 is a potential drug target for several diseases, including chronic pain and neurodegenerative disorders. Studies have shown that blocking the function of KRTAP22-2 may be effective in treating chronic pain and other neurodegenerative disorders.

One of the main advantages of targeting KRTAP22-2 is its potential to have a more targeted and effective treatment approach than many other drug targets. Because KRTAP22-2 is primarily expressed in the brain, blocking its function in this region may be more effective than blocking its function in other tissues. Additionally, because KRTAP22-2 is involved in multiple cellular processes, targeting it may be more effective than targeting individual proteins that are involved in a single process.

Another potential advantage of targeting KRTAP22-2 is its potential to be a once-weekly treatment. Because KRTAP22-2 is primarily expressed in the brain, blocking its function in this region may be effective for treating chronic pain and other neurodegenerative disorders. Additionally, because KRTAP22-2 is a protein that is expressed in low levels in other tissues, it may be possible to achieve a rapid and lasting effect by targeting it in the brain on a once-weekly basis.

In conclusion, KRTAP22-2 is a protein that is involved in the regulation of pain signaling and may be a potential drug target for several diseases. Its unique expression in the brain and its involvement in multiple cellular processes make it an attractive target for researchers and clinicians. Further research is needed to fully understand the function of KRTAP22-2 and its potential as a drug target.

Protein Name: Keratin Associated Protein 22-2

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins (By similarity)

The "KRTAP22-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP22-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets